Characteristics of schizophrenic patients using long-acting antipsychotic medications
GE Xiaolei1,2, ZHANG Weibo1,2, CHEN Chunmei1,2, ZHU Youwei1,2, LIU Yanli1,2, XIE Bin2,3, CAI Jun2,3, ZHU Yi1,2
1. Shanghai Mental Health Center Prevention and Control Office, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; 2. China Hospital Development Institute, Shanghai Jiao Tong University, Shanghai 200030, China; 3. Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
Abstract：Objective To investigate the characteristics of schizophrenic patients using long-acting antipsychotic medications, so as to provide the basis for applicable population of long-acting antipsychotic medications. Methods Data of schizophrenic patients using long-acting antipsychotic medications in Shanghai City from June 2020 to June 2022 were collected through Shanghai Mental Health Information Management System, and demographic characteristics, illness and medication use of patients were descriptively analyzed. Results A total of 2 684 schizophrenic patients using long-acting antipsychotic medications were included in the study, had a mean age of (46.92±12.39) years, with 1 246 males (46.42%) and 1 438 females (53.58%). There were 1 397 unemployed cases, accounting for 52.05%; 1 429 cases with an educational level in junior high school or below, accounting for 53.24%; 1 301 unmarried cases, accounting for 48.47%; 832 cases in poverty, accounting for 31.00%. The caregivers of patients were mainly their parents, with 1 507 cases accounting for 56.15%. The courses of illness were mainly ≤10 years and >10-20 years, with 860 cases each, both accounting for 32.04%; 1 963 cases with incomplete self-awareness, accounting for 73.14%; 1 570 cases hospitalized at least once, accounting for 58.49%. There were 2 486 cases with continuous medication, accounting for 92.62%. The main method of taking medication was given by others, with 1 947 cases accounting for 72.54%. The medication adherence was mainly taking medication on time and in the right amount, with 2 437 cases accounting for 90.80%. Conclusion The main characteristics of schizophrenic patients using long-acting antipsychotic medications are young, unmarried, and unemployed adults, with incomplete self-awareness, continuous medication and medication given by others.
[1] BIAGI E,CAPUZZI E,COLMEGNA F,et al.Long-acting injectable antipsychotics in schizophrenia:literature review and practical perspective,with a focus on aripiprazole once-monthly[J].Adv Ther,2017,34(5):1036-1048. [2] BAANDRUP L.Polypharmacy in schizophrenia[J].Basic Clin Pharmacol Toxicol,2020,126(3):183-210. [3] 戢汉斌,李四冬,巫珺,等.棕榈酸帕利哌酮对精神分裂症生活质量、自知力的影响[J].国际精神病学杂志,2016,43(5):791-793. [4] EINARSON T R,MAIA-LOPES S,GOSWAMI P,et al.Economic analysis of paliperidone longacting injectable for chronic schizophrenia in Portugal[J].J Med Econ,2016,19(9):913-921. [5] PARK E J,AMATYA S,KIM M S,et al.Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia[J].Arch Pharm Res,2013,36(6):651-659. [6] SAMALIN L,DE CHAZERON I,BLANC O,et al.Attitudes toward antipsychotic medications as a useful feature in exploring medication non-adherence in schizophrenia[J].Schizophr Res,2016,178(3):1-5. [7] BRISSOS S,VEGUILLA M R,TAYLOR D,et al.The role of long-acting injectable antipsychotics in schizophrenia:a critical appraisal[J].Ther Adv Psychopharmacol,2014,4(5):198-219. [8] FERVAHA G,TAKEUCHI H,LEE J,et al.Antipsychotics and amotivation[J].Neuropsychopharmacology,2015,40(6):1539-1548. [9] SUBOTNIK K L,CASAUS L R,VENTURA J,et al.Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia.a randomized clinical trial[J].JAMA Psychiatry,2015,72(8):822-829. [10] KHOURY A C E,PILON D,MORRISON L,et al.The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in medicaid patients with schizophrenia[J].Curr Med Res Opin,2019,35(3):395-405. [11] SUETANI S,SISKIND D,PHILLIPOU A,et al.Characteristics of people on long-acting injectable antipsychotics in Australia:data from the 2010 National Survey of High Impact Psychosis[J].Aust N Z J Psychiatry,2021,55(10):958-975. [12] 葛晓蕾,何思源,薛莉莉,等.2012—2018年上海市严重精神障碍应急事件特征分析[J].职业卫生与应急救援,2021,39(6):641-646. [13] 江弋舟,陈春梅,朱有为,等.社区不同性别精神分裂症病例危险行为发生风险预测模型的建立与验证[J].上海预防医学,2022,34(10):948-954. [14] 郝楷荣,纪家武,熊端华,等.严重精神障碍病例现状及管理调查分析[J].中国卫生标准管理,2021,12(2):23-25. [15] 葛晓蕾,张伟波,陈春梅,等.棕榈酸帕利哌酮注射液治疗社区精神分裂症病例的效果分析[J].上海预防医学,2023,35(7):684-688. [16] SOUZA A L R,GUIMARAES R A,DE ARAUJO VILELA D,et al.Factors associated with the burden of family caregivers of patients with mental disorders:a cross-sectional study[J].BMC Psychiatry,2017,17(1):353-362. [17] 聂莲莲,吴龙辉,江雁,等.精神分裂症病例监护人焦虑情绪的影响因素分析[J].预防医学,2021,33(11):1166-1169. [18] CURTO M,FAZIO F,ULIVIERI M,et al.Improving adherence to pharmacological treatment for schizophrenia:a systematic assessment[J].Expert Opin Pharmacother,2021,22(9):1143-1155. [19] KISHIMOTO T,HAGI K,KUROKAWA S,et al.Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia:a systematic review and comparative meta-analysis of randomised,cohort,and pre-post studies[J].Lancet Psychiat,2021,8(5):387-404. [20] 陈杰,宋立平,胡晓华.棕榈酸帕利哌酮注射剂与利培酮口服液治疗急性期精神分裂症的临床研究[J].中国临床药理学杂志,2017,33(4):308-311. [21] 姜璎慈,田吉,张芬,等.精神分裂症病例使用抗精神病长效治疗药物意愿调查分析[J].同济大学学报(医学版),2022,43(1):120-124.
